Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Neovasc Plans Next Steps After Thumbs Down From FDA Panel

Executive Summary

FDA advisory committee members said the trial population was too small and homogenous and did not establish that Neovasc’s Reducer effectively treats angina.

You may also be interested in...



Neovasc Maintains Investor Confidence Despite FDA Struggles; Sells $72M In Stock

Despite a recent unfavorable FDA advisory panel for its Reducer coronary sinus device, some investors showed their faith in the Canadian company by buying 36 million shares.

FDA Schedules Advisory Panel To Review Neovasc’s Angina Treatment

The US FDA's Circulatory System Devices Panel will meet on 27 October to evaluate Neovasc’s Reducer device, a minimally invasive treatment for drug-refractory angina.

US Sen. Duckworth Prods FEMA To Help Overstocked PPE Reach Potential Users

The Illinois senator pointed to an apparent mismatch between ongoing reports of equipment shortages, and alleged stockpiles of unsold masks.

Topics

Related Companies

UsernamePublicRestriction

Register

MT142998

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel